Conventional and alternative approaches for targeting PIK3CA and PTEN alterations in head and neck, breast, and other...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• PI3K/AKT/mTOR pathway alterations are prevalent in various human cancers.
• PIK3CA mutations occur in ~30% of HNSCC and 37% of breast cancer.
• PTEN loss, a PI3K pathway inhibitor, is observed in one-third of HNSCC.

Purpose of the Study:

• To review the impact of PIK3CA and PTEN alterations on cancer cell growth and metabolism.
• To summarize the clinical progress of p110α and related protein inhibitors.
• To describe novel strategies for targeting tumors with PIK3CA or PTEN alterations.

Main Methods:

• Literature review of genetic alterations in the PI3K/AKT/mTOR pathway.
• Analysis of the functional impact of these alterations on cancer cells.
• Summary of preclinical and clinical data for targeted therapies.

Main Results:

• PIK3CA and PTEN alterations significantly affect cancer cell growth and metabolism.
• Direct inhibitors of p110α are under active clinical evaluation.
• Emerging approaches are identifying new therapeutic vulnerabilities.

Conclusions:

• Targeting the PI3K/AKT/mTOR pathway is a promising strategy for HNSCC and breast cancer.
• Understanding PIK3CA and PTEN alterations is crucial for personalized cancer therapy.
• Continued research into targeted therapies and novel vulnerabilities is warranted.